Study of CS-3150 in Patients With Primary Aldosteronism

• Status: Completed
• Trial end date: 2017-07-20
• Target enrollment: 0
• Participant gender: All

Summary

To examine antihypertensive effect and safety of CS-3150 in patients with primary aldosteronism.

• Phase: N/A
• Accepts Healthy Volunteers?: No

Details

• Lead Sponsor: Daiichi Sankyo Co., Ltd.
• Treatments: Mineralocorticoid Receptor Antagonists

Criteria

Inclusion Criteria:

• Male and female subjects aged 20 years or older at informed consent

• Patients diagnosed primary aldosteronism by screening test of plasma aldosterone concentration (PAC) and aldosterone to renin ratio (ARR), and confirmatory testing

• Patients satisfying following blood pressure;

• sitting systolic blood pressure (SBP) ≥ 140 mmHg and <180 mmHg

• sitting diastolic blood pressure (DBP) ≥ 90 mmHg and <110 mmHg

Exclusion Criteria:

• Secondary hypertension except primary aldosteronism or hypertensive emergency

• Patients diagnosed diabetic nephropathy

• Patients with type 1 diabetes

• Estimated glomerular filtration rate (eGFR) < 30 mL/min/1.73m2

• Serum potassium level < 3.0 or ≥ 5.1 milliequivalent (mEq)/L